The relatively low molecular weight nucleic acid drugs, such as miRNA, ASO, siRNA, aptamers, and ribozymes, could be classified as oligonucleotides that do not express proteins directly. Small Nucleic Acid Drugs utilize nucleic acid, which refer to substances such as DNA and RNA that control genetic information, as drugs. These allow targeting of molecules such as mRNA and miRNA that cannot be targeted with traditional low molecular weight drugs and antibody medicines, and there is a great expectation for these drugs as next generation pharmaceuticals. Active research is being conducted globally as it is expected to lead to the creation of drugs which were previously intractable.
LPI (LP Information)' newest research report, the “Low Molecular Weight Nucleic Acid Drugs Industry Forecast” looks at past sales and reviews total world Low Molecular Weight Nucleic Acid Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Low Molecular Weight Nucleic Acid Drugs sales for 2023 through 2029. With Low Molecular Weight Nucleic Acid Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Low Molecular Weight Nucleic Acid Drugs industry.
This Insight Report provides a comprehensive analysis of the global Low Molecular Weight Nucleic Acid Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Low Molecular Weight Nucleic Acid Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Low Molecular Weight Nucleic Acid Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Low Molecular Weight Nucleic Acid Drugs and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Low Molecular Weight Nucleic Acid Drugs.
The global Low Molecular Weight Nucleic Acid Drugs market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.
United States market for Low Molecular Weight Nucleic Acid Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Low Molecular Weight Nucleic Acid Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Low Molecular Weight Nucleic Acid Drugs is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Low Molecular Weight Nucleic Acid Drugs players cover Novartis, Ionis, Nippon Shinyaku, Alnylam, Sarepta Therapeutics, MiNA Therapeutics, BioNTech and Moderna, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
This report presents a comprehensive overview, market shares, and growth opportunities of Low Molecular Weight Nucleic Acid Drugs market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
ASO
siRNA
Other
Segmentation by application
Cardiovascular Diseases
Hepatitis B
Hypertension
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Novartis
Ionis
Nippon Shinyaku
Alnylam
Sarepta Therapeutics
MiNA Therapeutics
BioNTech
Moderna
Key Questions Addressed in this Report
What is the 10-year outlook for the global Low Molecular Weight Nucleic Acid Drugs market?
What factors are driving Low Molecular Weight Nucleic Acid Drugs market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Low Molecular Weight Nucleic Acid Drugs market opportunities vary by end market size?
How does Low Molecular Weight Nucleic Acid Drugs break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

1 Scope of the Report 1.1 Market Introduction 1.2 Years Considered 1.3 Research Objectives 1.4 Market Research Methodology 1.5 Research Process and Data Source 1.6 Economic Indicators 1.7 Currency Considered 1.8 Market Estimation Caveats 2 Executive Summary 2.1 World Market Overview 2.1.1 Global Low Molecular Weight Nucleic Acid Drugs Annual Sales 2018-2029 2.1.2 World Current & Future Analysis for Low Molecular Weight Nucleic Acid Drugs by Geographic Region, 2018, 2022 & 2029 2.1.3 World Current & Future Analysis for Low Molecular Weight Nucleic Acid Drugs by Country/Region, 2018, 2022 & 2029 2.2 Low Molecular Weight Nucleic Acid Drugs Segment by Type 2.2.1 ASO 2.2.2 siRNA 2.2.3 Other 2.3 Low Molecular Weight Nucleic Acid Drugs Sales by Type 2.3.1 Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Type (2018-2023) 2.3.2 Global Low Molecular Weight Nucleic Acid Drugs Revenue and Market Share by Type (2018-2023) 2.3.3 Global Low Molecular Weight Nucleic Acid Drugs Sale Price by Type (2018-2023) 2.4 Low Molecular Weight Nucleic Acid Drugs Segment by Application 2.4.1 Cardiovascular Diseases 2.4.2 Hepatitis B 2.4.3 Hypertension 2.4.4 Other 2.5 Low Molecular Weight Nucleic Acid Drugs Sales by Application 2.5.1 Global Low Molecular Weight Nucleic Acid Drugs Sale Market Share by Application (2018-2023) 2.5.2 Global Low Molecular Weight Nucleic Acid Drugs Revenue and Market Share by Application (2018-2023) 2.5.3 Global Low Molecular Weight Nucleic Acid Drugs Sale Price by Application (2018-2023) 3 Global Low Molecular Weight Nucleic Acid Drugs by Company 3.1 Global Low Molecular Weight Nucleic Acid Drugs Breakdown Data by Company 3.1.1 Global Low Molecular Weight Nucleic Acid Drugs Annual Sales by Company (2018-2023) 3.1.2 Global Low Molecular Weight Nucleic Acid Drugs Sales Market Share by Company (2018-2023) 3.2 Global Low Molecular Weight Nucleic Acid Drugs Annual Revenue by Company (2018-2023) 3.2.1 Global Low Molecular Weight Nucleic Acid Drugs Revenue by Company (2018-2023) 3.2.2 Global Low Molecular Weight Nucleic Acid Drugs Revenue Market Share by Company (2018-2023) 3.3 Global Low Molecular Weight Nucleic Acid Drugs Sale Price by Company 3.4 Key Manufacturers Low Molecular Weight Nucleic Acid Drugs Producing Area Distribution, Sales Area, Product Type 3.4.1 Key Manufacturers Low Molecular Weight Nucleic Acid Drugs Product Location Distribution 3.4.2 Players Low Molecular Weight Nucleic Acid Drugs Products Offered 3.5 Market Concentration Rate Analysis 3.5.1 Competition Landscape Analysis 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023) 3.6 New Products and Potential Entrants 3.7 Mergers & Acquisitions, Expansion 4 World Historic Review for Low Molecular Weight Nucleic Acid Drugs by Geographic Region 4.1 World Historic Low Molecular Weight Nucleic Acid Drugs Market Size by Geographic Region (2018-2023) 4.1.1 Global Low Molecular Weight Nucleic Acid Drugs Annual Sales by Geographic Region (2018-2023) 4.1.2 Global Low Molecular Weight Nucleic Acid Drugs Annual Revenue by Geographic Region (2018-2023) 4.2 World Historic Low Molecular Weight Nucleic Acid Drugs Market Size by Country/Region (2018-2023) 4.2.1 Global Low Molecular Weight Nucleic Acid Drugs Annual Sales by Country/Region (2018-2023) 4.2.2 Global Low Molecular Weight Nucleic Acid Drugs Annual Revenue by Country/Region (2018-2023) 4.3 Americas Low Molecular Weight Nucleic Acid Drugs Sales Growth 4.4 APAC Low Molecular Weight Nucleic Acid Drugs Sales Growth 4.5 Europe Low Molecular Weight Nucleic Acid Drugs Sales Growth 4.6 Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Sales Growth 5 Americas 5.1 Americas Low Molecular Weight Nucleic Acid Drugs Sales by Country 5.1.1 Americas Low Molecular Weight Nucleic Acid Drugs Sales by Country (2018-2023) 5.1.2 Americas Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2018-2023) 5.2 Americas Low Molecular Weight Nucleic Acid Drugs Sales by Type 5.3 Americas Low Molecular Weight Nucleic Acid Drugs Sales by Application 5.4 United States 5.5 Canada 5.6 Mexico 5.7 Brazil 6 APAC 6.1 APAC Low Molecular Weight Nucleic Acid Drugs Sales by Region 6.1.1 APAC Low Molecular Weight Nucleic Acid Drugs Sales by Region (2018-2023) 6.1.2 APAC Low Molecular Weight Nucleic Acid Drugs Revenue by Region (2018-2023) 6.2 APAC Low Molecular Weight Nucleic Acid Drugs Sales by Type 6.3 APAC Low Molecular Weight Nucleic Acid Drugs Sales by Application 6.4 China 6.5 Japan 6.6 South Korea 6.7 Southeast Asia 6.8 India 6.9 Australia 6.10 China Taiwan 7 Europe 7.1 Europe Low Molecular Weight Nucleic Acid Drugs by Country 7.1.1 Europe Low Molecular Weight Nucleic Acid Drugs Sales by Country (2018-2023) 7.1.2 Europe Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2018-2023) 7.2 Europe Low Molecular Weight Nucleic Acid Drugs Sales by Type 7.3 Europe Low Molecular Weight Nucleic Acid Drugs Sales by Application 7.4 Germany 7.5 France 7.6 UK 7.7 Italy 7.8 Russia 8 Middle East & Africa 8.1 Middle East & Africa Low Molecular Weight Nucleic Acid Drugs by Country 8.1.1 Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Sales by Country (2018-2023) 8.1.2 Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Revenue by Country (2018-2023) 8.2 Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Sales by Type 8.3 Middle East & Africa Low Molecular Weight Nucleic Acid Drugs Sales by Application 8.4 Egypt 8.5 South Africa 8.6 Israel 8.7 Turkey 8.8 GCC Countries 9 Market Drivers, Challenges and Trends 9.1 Market Drivers & Growth Opportunities 9.2 Market Challenges & Risks 9.3 Industry Trends 10 Manufacturing Cost Structure Analysis 10.1 Raw Material and Suppliers 10.2 Manufacturing Cost Structure Analysis of Low Molecular Weight Nucleic Acid Drugs 10.3 Manufacturing Process Analysis of Low Molecular Weight Nucleic Acid Drugs 10.4 Industry Chain Structure of Low Molecular Weight Nucleic Acid Drugs 11 Marketing, Distributors and Customer 11.1 Sales Channel 11.1.1 Direct Channels 11.1.2 Indirect Channels 11.2 Low Molecular Weight Nucleic Acid Drugs Distributors 11.3 Low Molecular Weight Nucleic Acid Drugs Customer 12 World Forecast Review for Low Molecular Weight Nucleic Acid Drugs by Geographic Region 12.1 Global Low Molecular Weight Nucleic Acid Drugs Market Size Forecast by Region 12.1.1 Global Low Molecular Weight Nucleic Acid Drugs Forecast by Region (2024-2029) 12.1.2 Global Low Molecular Weight Nucleic Acid Drugs Annual Revenue Forecast by Region (2024-2029) 12.2 Americas Forecast by Country 12.3 APAC Forecast by Region 12.4 Europe Forecast by Country 12.5 Middle East & Africa Forecast by Country 12.6 Global Low Molecular Weight Nucleic Acid Drugs Forecast by Type 12.7 Global Low Molecular Weight Nucleic Acid Drugs Forecast by Application 13 Key Players Analysis 13.1 Novartis 13.1.1 Novartis Company Information 13.1.2 Novartis Low Molecular Weight Nucleic Acid Drugs Product Portfolios and Specifications 13.1.3 Novartis Low Molecular Weight Nucleic Acid Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.1.4 Novartis Main Business Overview 13.1.5 Novartis Latest Developments 13.2 Ionis 13.2.1 Ionis Company Information 13.2.2 Ionis Low Molecular Weight Nucleic Acid Drugs Product Portfolios and Specifications 13.2.3 Ionis Low Molecular Weight Nucleic Acid Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.2.4 Ionis Main Business Overview 13.2.5 Ionis Latest Developments 13.3 Nippon Shinyaku 13.3.1 Nippon Shinyaku Company Information 13.3.2 Nippon Shinyaku Low Molecular Weight Nucleic Acid Drugs Product Portfolios and Specifications 13.3.3 Nippon Shinyaku Low Molecular Weight Nucleic Acid Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.3.4 Nippon Shinyaku Main Business Overview 13.3.5 Nippon Shinyaku Latest Developments 13.4 Alnylam 13.4.1 Alnylam Company Information 13.4.2 Alnylam Low Molecular Weight Nucleic Acid Drugs Product Portfolios and Specifications 13.4.3 Alnylam Low Molecular Weight Nucleic Acid Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.4.4 Alnylam Main Business Overview 13.4.5 Alnylam Latest Developments 13.5 Sarepta Therapeutics 13.5.1 Sarepta Therapeutics Company Information 13.5.2 Sarepta Therapeutics Low Molecular Weight Nucleic Acid Drugs Product Portfolios and Specifications 13.5.3 Sarepta Therapeutics Low Molecular Weight Nucleic Acid Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.5.4 Sarepta Therapeutics Main Business Overview 13.5.5 Sarepta Therapeutics Latest Developments 13.6 MiNA Therapeutics 13.6.1 MiNA Therapeutics Company Information 13.6.2 MiNA Therapeutics Low Molecular Weight Nucleic Acid Drugs Product Portfolios and Specifications 13.6.3 MiNA Therapeutics Low Molecular Weight Nucleic Acid Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.6.4 MiNA Therapeutics Main Business Overview 13.6.5 MiNA Therapeutics Latest Developments 13.7 BioNTech 13.7.1 BioNTech Company Information 13.7.2 BioNTech Low Molecular Weight Nucleic Acid Drugs Product Portfolios and Specifications 13.7.3 BioNTech Low Molecular Weight Nucleic Acid Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.7.4 BioNTech Main Business Overview 13.7.5 BioNTech Latest Developments 13.8 Moderna 13.8.1 Moderna Company Information 13.8.2 Moderna Low Molecular Weight Nucleic Acid Drugs Product Portfolios and Specifications 13.8.3 Moderna Low Molecular Weight Nucleic Acid Drugs Sales, Revenue, Price and Gross Margin (2018-2023) 13.8.4 Moderna Main Business Overview 13.8.5 Moderna Latest Developments 14 Research Findings and Conclusion